Life Molecular Imaging

Life Molecular Imaging (LMI) is a global pharmaceutical and biotechnology company dedicated to the research, development, and commercialization of innovative radiopharmaceuticals for molecular imaging. Originally formed in 2012 following the acquisition of the molecular imaging research portfolio from Bayer Pharma AG, the company has established itself as a leader in the field of Positron Emission Tomography (PET) tracers. LMI's primary mission is to pioneer diagnostic tools that enable the early detection and characterization of chronic and life-threatening conditions, with a specific focus on neurodegenerative disorders, such as Alzheimer's disease, and cardiovascular diseases.

The company's flagship product, Neuraceq® (florbetaben F18), is a radioactive diagnostic agent approved for use in PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment. This technology plays a critical role in the evaluation of Alzheimer's disease and other causes of cognitive decline. Headquartered in Berlin, Germany, with subsidiaries in the United States and the United Kingdom, Life Molecular Imaging operates an integrated business model that includes research and development laboratories, a network of cyclotrons, and radiopharmacies. In 2025, the company was acquired by Lantheus Holdings, further strengthening its capabilities and reach in the radiopharmaceutical market while continuing to advance its pipeline of novel imaging agents.